1. Home
  2. SEV vs PMN Comparison

SEV vs PMN Comparison

Compare SEV & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SEV

Aptera Motors Corp.

N/A

Current Price

$2.58

Market Cap

103.2M

Sector

Industrials

ML Signal

N/A

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

N/A

Current Price

$10.58

Market Cap

115.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SEV
PMN
Founded
2019
2004
Country
United States
Canada
Employees
46
N/A
Industry
Auto Manufacturing
Pharmaceuticals and Biotechnology
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.2M
115.5M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
SEV
PMN
Price
$2.58
$10.58
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$42.67
AVG Volume (30 Days)
225.7K
35.9K
Earning Date
05-16-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17,757.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.29
$0.29
52 Week High
$11.24
$27.40

Technical Indicators

Market Signals
Indicator
SEV
PMN
Relative Strength Index (RSI) 40.05 40.14
Support Level $2.49 $10.55
Resistance Level $3.26 $13.80
Average True Range (ATR) 0.15 0.66
MACD -0.04 0.15
Stochastic Oscillator 12.50 56.55

Price Performance

Historical Comparison
SEV
PMN

About SEV Aptera Motors Corp.

Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: